From: Role of chest CT scan in patients with preexisting cancer and COVID-19 pneumonia
All cancer | Gastrointestinal | Hematologic | |||||
---|---|---|---|---|---|---|---|
Variable | Dead/alive | OR1 | OR2 | Dead/alive | OR2 | Dead/alive | OR2 |
RSNA classification | |||||||
Negative | 6/32 | Ref | Ref | 5/6 | Ref | 1/12 | Ref |
Atypical | 20/38 | 2.80 (1.005–7.83) | 2.44 (0.85–6.98) | 7/10 | 0.73 (0.14–3.77) | 5/5 | 11.47 (0.89–147.18) |
Indeterminate | 17/39 | 2.32 (0.82–6.58) | 2.24 (0.78–6.43) | 8/9 | 1.12 (0.22–5.61) | 4/10 | 4.21 (0.37–47.52) |
Typical | 45/69 | 3.47 (1.34–8.98) | 2.99 (1.14–7.86) | 17/16 | 1.39 (0.31–6.17) | 9/24 | 2.28 (0.21–24.26) |
CT score | |||||||
0 | 26/69 | Ref | Ref | 12/16 | Ref | 6/17 | Ref |
≤ 18 | 7/32 | 0.58 (0.22–1.47) | 0.59 (0.23–1.53) | 2/7 | 0.47 (0.07–2.91) | 4/9 | 1.10 (0.22–5.49) |
> 18 | 55/77 | 1.89 (1.07–3.34) | 1.81 (1.01–3.23) | 23/18 | 1.94 (0.69–5.45) | 9/25 | 0.53 (0.13–2.16) |
Pattern of involvement | |||||||
Normal | 26/69 | Ref | Ref | 12/16 | Ref | 6/17 | Ref |
Pure GGO | 14/38 | 0.99 (0.46–2.12) | 0.88 (0 .40–1.93) | 4/10 | 0.48 (0.11–2.17) | 4/14 | 0.51 (0.10–2.55) |
Mixed GGO and consolidation | 48/70 | 1.84 (1.03–3.30) | 1.86 (1.03–3.36) | 21/15 | 2.40 (0.81–7.11) | 9/20 | 0.79 (0.20–3.07) |
Predominant GGO | 41/65 | 1.69 (0.93–3.08) | 1.68 (0.91–3.09) | 19/14 | 2.34 (0.77–7.06) | 8/19 | 0.70 (0.17–2.86) |
Predominant consolidation | 7/5 | 3.76 (1.09–12.9) | 4.55 (1.28–16.17) | 2/1 | 3.17 (0.23–42.3) | 1/1 | 2.29 (0.11–45.14) |
Other abnormality | |||||||
Crazy paving | 16/23 | 1.49 (0.74–3.00) | 1.36 (0.66–2.80) | 6/5 | 1.51 (0.39–5.78) | 3/6 | 0.72 (0.13–3.93) |
Pleural effusion | 43/46 | 2.74 (1.60–4.68) | 2.94 (1.69–5.12) | 17/11 | 2.52 (0.93–6.85) | 8/8 | 5.34 (1.36–20.90) |
Pericardial effusion | 5/6 | 1.72 (0.51–5.82) | 1.75 (0.50–6.06) | 1/2 | 0.93 (0.07–11.52) | 1/2 | 1.20 (0.08–16.27) |
Lymphadenopathy | 8/25 | 0.61 (0.26–1.41) | 0.58 (0.25–1.37) | 2/4 | 0.54 (0.09–3.29) | 3/7 | 0.92 (0.20–4.28) |
Centrilobular nodules | 14/13 | 2.40 (1.07–5.36) | 2.89 (1.25–6.65) | 7/1 | 16.88 (1.71–166.38) | 2/3 | 2.55 (0.32–19.99) |
Mass | 7/7 | 2.11 (0.71–6.21) | 2.18 (0.72–6.59) | 1/0 | - | 2/2 | 5.68 (0.54–59.19) |
Architectural distortion | 13/9 | 3.25 (1.33–7.94) | 3.76 (1.50–9.40) | 6/2 | 7.13 (1.19–42.74) | 3/1 | 10.53 (0.94–117.32) |
Nodular metastatic | 10/12 | 1.77 (0.73–4.28) | 1.72 (0.70–4.24) | 4/2 | 2.40 (0.37–15.50) | 1/1 | 5.40 (0.20–140.97) |